ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Population preventable fraction of total multiple sclerosis risk associated with non-specific effects of vaccinations against hepatitis B virus and influenza A and B viruses in a middle eastern country.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to quantify the population attributable (or prevented) fraction (PAR or PPF) of common risk factors for multiple sclerosis (MS) including family history of MS and vaccine uptake against influenza A and B viruses and hepatitis B virus.
methodsConfirmed MS cases and MS-free controls pair-matched on age (± 5 years), sex and nativity with cases were enrolled. Data were collected through face-to-face interviews both from the cases and controls. An unconditional multivariable logistic regression model was used to analyze the data by including matching factors i.e., age, sex, and nativity as confounders and MS family history and vaccine uptake against influenza viruses and hepatitis B virus as exposures. The adjusted odds ratios and their 95% confidence intervals (CI) were used to compute PAR for family history of MS and PPFs for vaccine uptake against HBV and influenza virus along with their respective 95% CIs.
resultsA total of 110 MS cases, and their 110 pair-matched controls were enrolled. The PAF for family history of MS revealed that 22% of MS risk in the population is contributed by family history of MS (PAF = 0.22; 95% CI: 0.10-0.32). The PPFs for vaccination uptake against influenza viruses and/or hepatitis B virus were associated with a significant nonspecific protection against MS risk by 20% (PPF = 0.20; 95% CI: 0.004-0.43) or 30% (PPF = 0.30; 95% CI: 0.03-0.65) respectively. Moreover, the computed joint PPF for vaccination uptake against influenza viruses and hepatitis B virus showed a significantly increased 44% non-specific protection against MS risk (PPF = 0.44; 95% CI: 0.03-0.80).
conclusionsFamilial history of MS is associated with 22% population attributable fraction for MS risk, whereas vaccine uptake against influenza viruses or hepatitis B virus conferred a nonspecific protection with population prevented fractions of 20% and 30% respectively suggesting a substantial potential for public health interventions to minimize MS risk in this and other similar settings.
Indexed as
Identifiers
40261520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.